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Underlying Pathophysiology
Skeletal Muscle Pathophysiology in Malignant Hyperthermia 
• Incidence of 1:10,000 to 1:250,000 anesthetics; prevalence of genetic 
abnormalities may be as high as 1:400 (Rosenberg et al., 2015).
• On average, patients require three anesthetics before a crisis is 
triggered (Rosenberg et al., 2015). 
• All ethnic groups affected in all parts of the world (Rosenberg et al., 
2015).
• MH reactions are more common in males (62%) than females (38%) 
(Gupta & Hopkins, 2017).
• Highest incidence of disease presentation in young adults, with a 
“mean age of all patients experiencing reactions of 18.3 years old” 
(Rosenberg et al., 2015). 
Signs and Symptoms
Early Signs & Symptoms (Gupta & Hopkins, 2017)
• Sudden, unexplained rise in end-tidal carbon 
dioxide (EtCO2).
• Rapid heart rate (tachycardia).
• Tachypnea in the spontaneously breathing       
patient.
• Diaphoresis.
• Masseter muscle or generalized muscle rigidity.
• Unexplained fever in the immediate
postoperative period.
Late Signs & Symptoms (Gupta & Hopkins, 2017)
• Hyperthermia caused by sustained muscle    
contraction.
• Lactic acidosis.
• Hyperkalemia, peaked T-waves.
• Myoglobinemia from muscle breakdown 
(similar to rhabdomyolysis).
• Dark colored urine.
• Hypotension.
• Cardiac arrhythmias.
• Coagulopathies and disseminated intravascular 
coagulopathy.
• Cardiovascular collapse and death.
Normal Skeletal Muscle Physiology
• Action potential from motor neuron travels to presynaptic terminal.
• Acetylcholine is released into the synaptic cleft and binds with the postsynaptic 
skeletal muscle nicotinic membrane receptor, which then depolarizes adjacent muscle fibers.
• Calcium (Ca2+) channels open, Ca2+ rushes into cell, and additional Ca2+ is released from the 
sarcoplasmic reticulum (SR) via the ryanodine receptors (Hernandez-Ochoa & Schneider, 
2018). 
• Normal skeletal muscle contains ryanodine receptors which regulate Ca2+ movement from 
the SR to the cytoplasm of the muscle cell (Litman et al., 2018).
• Ca2+ binds to troponin enabling cross-bridging of actin & myosin, causing muscle 
contraction using adenosine triphosphate (ATP) to create work and heat (Gupta & Hopkins,
2017).
• Ca2+ is then removed from the cytoplasm of the cell back into the SR via the SERCA
channel to enable muscle fiber relaxation (Gupta & Hopkins, 2017). This process is collectively 
known as excitation-contraction coupling (ECC). 
• MH-susceptible patients demonstrate a defective ryanodine receptor (RYR1) related to 
the SR in skeletal muscle cells (Rosenberg et al., 2015).
• The defective RYR1 receptor results in unopposed release of SR Ca++ stores into the 
cytoplasm in the presence of triggering anesthetic agents (Litman et al., 2018).
• The SERCA channel of the SR Ca2+ sequestering mechanism becomes overwhelmed, 
causing Ca2+ to build up in the skeletal muscle cell cytoplasm leading to sustained muscle 
contraction (Litman et al., 2018).
• Sustained contraction causes increased energy use, dramatic rises in CO2 production,
increased O2 consumption, and production of heat and lactic acid (Gupta & Hopkins, 2017). 
Figure 3. Pathologic Process of Defective RYR1 Receptor (Gupta & Hopkins, 2017).
• 3 genetic alterations associated with MH susceptibility: CACNA1S, 
STAC3, and RYR1 genes (Litman et el., 2018). 
• Autosomal Dominance: 50% of offspring of affected individuals inherit 
genetic defect.
• All family members of a patient with known MH susceptibility must 
also be considered MH susceptible until proven otherwise (MHAUS, 2020). 
• Patients with certain myopathies have genetic defects associated with 
MH and must be considered susceptible to MH by the anesthetist (Litman 
et al., 2018):
• Central Core Disease
• Duchenne Muscular Dystrophy
• Congenital Fiber Disproportion
• Multiminicore Myopathy
• Native America Myopathy




Figure 1. Myopathies Associated with MH (Litman et al., 2018).
Figure 2. Normal Skeletal Muscle Physiology (Hernandez-Ochoa & Schneider, 2018).
Significance of Pathophysiology
• Dysregulation of Ca2+ in skeletal muscle causes 
hypermetabolic state and high demand for ATP 
(Gupta & Hopkins, 2017).
• Increased CO2 production and O2 consumption
leads to a mixed acidosis (Gupta & Hopkins, 2017).
• Sustained muscle contraction compromises cell 
membrane integrity causing hyperkalemia, 
myoglobinemia, rhabdomyolysis, and acute kidney 
injury (Gupta & Hopkins, 2017). 
• Hyperthermia from high metabolic state 
predisposes patient to DIC and bleeding in the 
presence of invasive surgical procedures.
• Hypercapnia, hyperkalemia, and tachycardia 
predispose the patient to cardiac arrhythmias, 
cardiovascular collapse, and death. 
Implications for Nurse Anesthetists
• Stop administration of triggering agents.
• Alert surgeon of the need to stop  
procedure.
• Hyperventilate with 100% FiO2, attach 
charcoal filters to breathing circuit if 
available, and change breathing circuit and 
gas absorbent canister.
• Call for assistance from other anesthesia
providers.
• Give Dantrolene 2.5mg/kg initial dose, 
1mg/kg as needed for persistent signs of
MH.
• Cool patient to core temperature <38.5°C 
via cooling blankets, cold IV fluid, and cold 
gastric/ bladder lavages as necessary.
• Insert arterial and large-bore IV/ central 
line for blood pressure monitoring, frequent 
lab draws, and IV fluid administration.
• IV fluids to prevent kidney injury and 
cardiovascular collapse.
• Treat electrolyte & pH abnormalities.
• Treat cardiac arrhythmias as needed. 
• Treat coagulopathies as needed.
• Ensure patient is monitored in critical 
care unit for a minimum of 24 hours after 
MH signs and symptoms are controlled.
*All management information from Gupta & 
Hopkins, 2017.
Prevention: the goal of anesthetic management of MH-susceptible patients is prevention of a
crisis, including ensuring the anesthesia machine has been properly prepared by flushing with 
high-flow O2 for brand-specific timeframe, charcoal filters applied to inspiratory and expiratory 
limbs of circuit if available, anesthesia gas vaporizers have been removed from the machine, 
and administering no triggering agents (MHAUS, 2020). 
MH-Triggering Agents:
Diagnosis
• Based on clinical presentation: unexplained 
EtCO2, muscle rigidity, tachycardia, acidosis, 
hyperthermia, and hyperkalemia (Rosenberg et al., 
2015).
• Gold Standard: caffeine/halothane contraction 
test (CHCT)- muscle biopsy from thigh is exposed to 
caffeine and/or halothane. A positive result consists 
of sustained visible contraction upon exposure to 
triggering agents (Gupta & Hopkins, 2017).
• CHCT is painful, expensive, and only performed
at a small amount of specialized testing centers






Management of an MH Crisis:
*It is the responsibility of the anesthetist to recognize and treat an MH crisis.
Dantrolene Sodium: the only know treatment for MH works by “depressing the ECC in 
skeletal muscle by binding to the RYR1 receptor and decreasing intracellular calcium 
concentration” (Ratto & Joyner, 2020). Comes in two preparations:
• Dantrium™ IV (20mg dantrolene/vial; 
requires 60mL sterile H2O for reconstitution).
• Ryanodex™ IV (250mg dantrolene/vial; 
requires 5mL sterile water for reconstitution).
Conclusions
• Malignant Hyperthermia is a rare, autosomal dominant skeletal muscle disorder that can have 
an insidious onset, difficult diagnosis, and lead to morbidity and mortality in the surgical patient.
• MH crisis-triggering agents are the depolarizing neuromuscular paralytic succinylcholine and 
anesthetic gasses halothane, desflurane, sevoflurane, and isoflurane. MH can occur in patients 
who have received anesthesia with these agents in the past (Nagelhout	&	Plaus,	2018,	p	775).
• It is the responsibility of the anesthetist to perform an adequate preoperative patient history 
evaluation to uncover possible MH susceptibility in the surgical patient. Patients with a family
history of MH or associated skeletal muscle disorder must be treated as MH-susceptible until 
proven otherwise via CHCT at an approved facility.
• Failure to detect an MH crisis can lead to kidney failure, profound acidosis, coagulopathies, 
rhabdomyolysis, cardiac dysrhythmias, cardiovascular collapse, and death (Seifert	et	al.,	2015).	
• Early detection of an MH crisis and treatment with Dantrolene affords the patient with the
greatest chance of survival in the intraoperative and postoperative period. An MH crisis requires
an adequately prepared surgical team and high level of coordinated care to ensure optimal
outcomes in patients exhibiting a malignant hyperthermia crisis. 
References
